Biotech's movers for the week of March 2nd, 2026 and a preview of the week ahead
Reviewing some of biotech's biggest moves over the last week, including uniQuire, Day One Biopharmaceuticals, and Aardvark Therapeutics.
24 minutes ago
AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner
Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think about improving selectivity and sensitivity. Plus, how AI is changing the field, what it takes to be differentiated, and implications of new startups sharing less knowledge than has been traditionally done. Chapters The current state of the art – 1:05 What is coming in the next y
3 days ago
Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis
CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addition to the CAR. Plus, an update on the company's liver transplant study, a program that he says will need a partner to move forward.
5 days ago
.png){kind=logo}
